Atypical Hemolytic Uremic Syndrome (aHUS) Therapeutics Pipeline Analysis

CITY, Country, 2019-Jul-26 — /EPR Network/ —

Atypical hemolytic uremic syndrome (aHUS), also known as non-diarrhea – associated hemolytic uremic syndrome, is a rare disease characterized by hemolytic anemia, thrombocytopenia, acute kidney failure and uremia.

Download the sample report at:

The signs and symptoms of aHUS include formation of tiny blood clots in various small blood vessels of the body. These clots reduce or prevent proper blood flow to various organs of the body, especially the kidneys. aHUS is a complex disorder; and certain genetic, environmental and immunologic factors plays significant role in its development.

Get the detailed analysis at:

Company lile ChemoCentryx Inc. is in the process of developing avacopan, an orally-administered drug candidate, that inhibits the complement C5a receptor for the treatment of aHUS. Omeros Corporation, Greenovation Biotech GmbH, and Laboratoris Sanifit S.L. are some other companies developing therapeutic agents for aHUS.

Make enquiry before purchase at:

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

 About Us:

Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455


Connect with us on: LinkedIn | Twitter | Facebook

Matched content

Editor’s pick

Do NOT follow this link or you will be banned from the site!